Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products

Cardiology

Volumn 110, Issue 3, 2008, Pages 182-190

  Liang, Yao Jen ^a   Shyu, Kou Gi ^b,c   Wang, Bao Wie ^c   Lai, Ling Ping ^a,d,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

C reactive protein; Lipid metabolism; Receptors; Statins; Vascular cell adhesion molecule 1

Indexed keywords

C REACTIVE PROTEIN; CD32 ANTIGEN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVALONIC ACID; SIMVASTATIN; SMALL INTERFERING RNA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

C-REACTIVE PROTEIN; CELL ADHESION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MEVALONIC ACID; MONOCYTES; NF-KAPPA B; POLYISOPRENYL PHOSPHATES; RECEPTORS, IGG; RNA, SMALL INTERFERING; SESQUITERPENES; SIMVASTATIN; UMBILICAL VEINS; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 44849126759     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111928     Document Type: Article

References (35)

1. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
2. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
3. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L: C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647-655.
4. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, et al: Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2005;102:8309-8314.
5. Agrawal A: CRP after 2004. Mol Immunol 2005;42:927-930.
6. Trion A, de Maat MPM, Jukema JW, van der Laarse A, Maas MC, Offerman EH, et al: No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E * 3-Leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 2005;25:1635-1640.
7. Reifenberg K, Lehr HA, Baskal D, Wiese E, Schaefer SC, Black S, et al: Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer. Arterioscler Thromb Vasc Biol 2005;25:1641-1646.
8. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-1006.
9. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW: The major receptor for C-reactive protein on leukocytes is Fcγ receptor II. J Exp Med 1999;190:585-590.
10. Vielma S, Virella G, Gorod A, Lopes-Virella M: Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of Fcγ receptor II (FcγRII). Clin Immunol 2002;104:265-273.
11. Devaraj S, Du Clos TW, Jialal I: Binding and internalization of C-reactive protein by Fcγ receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005;25:1359-1363.
12. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3121-3143.
13. Hillyard DZ, Cameron AJ, McDonald KJ, Thomson J, MacIntyre A, Shiels PG, et al: Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis 2004;175:305-313.
14. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM: Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006;114:681-687.
15. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, et al: Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006;188:51-58.
16. Taylor KE, Giddings JC, van den Berg CW: C-reactive protein-induced in vitro endothelial cell activation is an artifact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005;25:1225-1230.
17. Van der Harst P, Voors AA, van Gilst WH, Bohm M, van Veldhuisen DJ: Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006;71:443-454.
18. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;94:685-696.
19. Beckman JA, Creager MA: The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med 2006;16:156-162.
20. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al: Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-1831.
21. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Pitsavos C, Vlachopoulos C, et al: Effects of atorvastatin on reactive hyperemia and Inflammatory process in patients with congestive heart failure. Atherosclerosis 2005;178:359-363.
22. Yeh ET, Anderson HV, Pasceri V, Willerson JT: C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001;140:974-975.
23. Manolov DE, Rocker C, Hombach V, Nienhaus GU, Torzewski J: Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcγRIIa. Arterioscler Thromb Vasc Biol 2004;24:2372-2377.
24. Devaraj S, Davis B, Simon SI, Jialal I: CRP promotes monocyte-endothelial cell adhesion via Fcγ receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol 2006;291:H1170-H1176.
25. Liang YJ, Shyu KG, Wang BW, Lai LP: C-reactive protein activates the nuclear factor-κB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardio 2006;40:412-420.
26. Escribano-Burgos M, Lopez-Farre A, del Mar Gonzalez M, Macaya A, Garcia-Mendez A, Mateos-Caceres PJ, et al: Effect of C-reactive protein on Fcγ receptor II in cultured bovine endothelial cells. Clin Sci 2005;108:85-91.
27. Pfeiffer JR, Howes PS, Waters MA, Hynes ML, Schnurr PP, Demidenko E, et al: Levels of expression of Fcγ receptor IIA (CD32) are decreased on peripheral blood monocytes in patients with severe atherosclerosis. Atherosclerosis 2001;155:211-218.
28. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I: Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-α activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-κ-B pathway. J Am Coll Cardiol 2004;43:1481-1488.
29. De Martin R, Hoeth M, Hofer-Warbineck R, Schmid JA: The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000;20:E83-E88.
30. Pasceri V, Cheng JS, Willerson JT, Yeh ET: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534.
31. Lin R, Liu J, Peng N, Yang G Gan W, Wang W: Lovastatin reduces nuclear factor κB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 2005;28:1630-1634.
32. Wang HR, Li JJ, Huang CX, Jiang H: Fluvastatin inhibits the expression of tumor necrosis factor-α and activation of nuclear factor-κB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005;353:53-60.
33. Chang LT, Sun CK, Chiang CH, Wu CJ, Chua S, Yip HK: Impact of simvastatin and losartan on anti-inflammatory effect: in vitro study. J Cardiovasc Pharmacol 2007;49:20-26.
34. Maack C, Kartes T, Kilter H, Schafers HJ, Nickenig G, Bohm M, et al: Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation 2003;108:1567-1574.
35. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, et al: Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002;277:15309-15316.